Silence Therapeutics plc
Silence Therapeutics plc (SLN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · SLN · as of Sep 30, 2025
Ownership Breakdown
54
Institutional Holders
▼ 3 vs Q2
$96.43M
Total Inst. Value
▼ $11.68M vs Q2
47.23M
Shares Outstanding
freeFloat 79.75%
19.70M
13F Shares Held
▼ 69,532 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
SLN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TCG CROSSOVER MANAGEMENT, LLC pharmaceutical preparations | 3.03M | 6.42% | 6.42% | $15.74B | Nov 17, 2025 | — held |
SIREN, L.L.C. pharmaceutical preparations | 2.91M | 6.16% | 6.16% | $15.11B | Nov 13, 2025 | — held |
REDMILE GROUP, LLC pharmaceutical preparations | 2.16M | 4.58% | 4.58% | $11.24B | Nov 14, 2025 | — held |
LOMBARD ODIER ASSET MANAGEMENT (USA) CORP pharmaceutical preparations | 1.84M | 3.91% | 3.91% | $7.12B | Nov 14, 2025 | ▼ 4.8K |
MORGAN STANLEY pharmaceutical preparations | 1.21M | 2.56% | 2.56% | $6.27B | May 27, 2026 | ▼ 4.0K |
VIVO CAPITAL, LLC pharmaceutical preparations | 1.11M | 2.34% | 2.34% | $5.74B | Nov 14, 2025 | — held |
NANTAHALA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.04M | 2.21% | 2.21% | $5.41B | Nov 14, 2025 | — held |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. pharmaceutical preparations | 970.1K | 2.05% | 2.05% | $5.03B | Nov 14, 2025 | — held |
NEXTECH INVEST, LTD. pharmaceutical preparations | 952.4K | 2.02% | 2.02% | $4.94B | Nov 14, 2025 | — held |
IKARIAN CAPITAL, LLC pharmaceutical preparations | 900.8K | 1.91% | 1.91% | $1.31B | Nov 14, 2025 | ▲ 27.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
17
Increased
+314.5K shares2
New Positions
first time holders16
Decreased
−241.0K shares0
Sold Out
fully exitedNet shares change (top 50)
+73.5K
+314.5K / −241.0K
Net new holders
+3
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
SLN insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Griffiths Richard Ian 10 percent owner | Aug 3, 2025 | Purchase | 20,000 | $5.45 | $109.0K | 11.83M | Form 4 ↗ |
Griffiths Richard Ian 10 percent owner | Oct 27, 2025 | Purchase | 2,000 | $7.75 | $15.5K | 11.83M | Form 4 ↗ |
Griffiths Richard Ian 10 percent owner | Oct 27, 2025 | Sale | 2,000 | $7.75 | $15.5K | 11.82M | Form 4 ↗ |
Griffiths Richard Ian 10 percent owner | Aug 3, 2025 | Sale | 20,000 | $5.45 | $109.0K | 11.81M | Form 4 ↗ |
Ede-Golightly James director | Jan 2, 2026 | Award | 90,000 | $2.05 | $184.5K | 90.0K | Form 4 ↗ |
MCINERNEY TIMOTHY director | Jan 2, 2026 | Award | 90,000 | $2.05 | $184.5K | 90.0K | Form 4 ↗ |
Romano Steven J. EVP and Chief R&D Officer | Jan 2, 2026 | Award | 300,000 | $2.05 | $615.0K | 300.0K | Form 4 ↗ |
HELLUMS RHONDA LYNETTE Chief Financial Officer | Jan 2, 2026 | Award | 375,000 | $2.05 | $768.7K | 375.0K | Form 4 ↗ |
Lemus David director | Jan 2, 2026 | Award | 90,000 | $2.05 | $184.5K | 90.0K | Form 4 ↗ |
Ross Iain Interim PEO | Dec 18, 2025 | Award | 900,000 | $2.08 | $1.87M | 900.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Silence Therapeutics plc (SLN) is primarily owned by institutional investors, who hold approximately 41.7% of total shares outstanding. Company insiders own approximately 20.25%, while retail and public investors account for the remaining 38.03%.
The largest institutional shareholder of Silence Therapeutics plc is TCG CROSSOVER MANAGEMENT, LLC, holding approximately 3.03 million shares — equal to 6.42% of outstanding shares — as of September 30, 2025.
A total of 54 institutional investors currently hold SLN stock, with a combined institutional value of approximately $96,433,443 as of the most recent 13F filing period.
Frequently asked questions
SLN ownershipSilence Therapeutics plc (SLN) is primarily owned by institutional investors, who hold approximately 41.7% of shares. The largest shareholder is TCG CROSSOVER MANAGEMENT, LLC with a 6.42% stake. Company insiders hold 20.25%. Data sourced from SEC Form 13F as of September 30, 2025.